A laboratory instrument produces a number. The tempting next step is to treat that number like an answer.
But imagine four suitcases arriving at baggage claim with nearly identical tags. The tags help you narrow the possibilities. They do not tell you what is inside each bag.
Peptide analysis can present the same problem. A signal may show that a molecule is slightly heavier than expected, but that extra mass does not automatically reveal what happened. The difference might reflect a real chemical change. It might come from an extra amino-acid building block. It might even be a temporary companion that attached itself only while the molecule was entering the instrument.
A peer-reviewed study published online on September 3, 2026 makes that point unusually well. Researchers investigating a complex 36-residue peptide found that a family of signals near +56 Da had at least four analytically distinct origins.1 A dalton, abbreviated Da, is simply a unit scientists use to describe molecular mass. The important part is not the unit. It is that several very different events can produce signals that appear similar at first.
That is why a laboratory result must be interpreted as an evidence chain, not a single number.
First, What Does a “+56” Signal Mean?
Mass spectrometry is often described as a molecular scale. That is useful, but incomplete. A mass spectrometer does not place a vial on a platform and display one weight. It turns molecules into charged particles, separates those particles according to their mass-to-charge behavior, and records a spectrum containing many signals.
If the intended peptide produces an expected molecular mass and another component appears about 56 Da heavier, analysts may describe the second component as a +56 Da species. That description tells us how far the signal sits from the target. It does not, by itself, identify the structure responsible for the difference.
This distinction is easy to miss because labels sound definitive. Once something is called “the +56 impurity,” the name can quietly become the explanation. The new study shows why that shortcut is risky.
“Apparent +56 Da impurities arise from multiple mechanistically distinct sources.” — Liu et al., Journal of Pharmaceutical and Biomedical Analysis1
The word apparent is doing important work. It signals that the first observation is provisional. The analyst has seen a difference. The cause still has to be established.
How Peptide Manufacturing Creates Look-Alikes
Peptides are chains of amino acids. In common chemical manufacturing approaches, the chain is built one building block at a time. Each addition must happen in the correct order and at the correct location.
That process would be difficult if every reactive part of every amino acid were available at once. Chemists therefore use temporary protective groups, which work like small caps. A cap blocks a reactive site until the process is ready for it. At the end of synthesis, the caps are removed and the peptide is released from its solid support.
The European Medicines Agency describes this as a repeated series of coupling, washing, deprotection, and capping steps, followed by a final cleavage and deprotection stage.2 Each step is purposeful. Each step can also create characteristic byproducts if the chemistry takes an unintended route.
In the September study, the researchers showed that one important group of +56 Da impurities came from tert-butylation. In plain language, a small carbon-rich fragment associated with the protecting chemistry became attached to the peptide when it was not supposed to remain there.1
The team identified more than one pathway. A tert-butyl group could attach to a sulfur-containing cysteine position. Related transfer chemistry could also affect tyrosine or the peptide’s terminal region. These were genuine, covalent changes to the molecule. The extra mass was really part of the altered peptide.
That matters because a real manufacturing byproduct calls for a manufacturing response. The researchers tested changes in protecting-group selection and coupling conditions and showed that targeted changes could suppress major unwanted products.1
Testing therefore did more than find a strange peak. It connected the peak to a probable mechanism and helped point toward process improvement.
The Extra Building Block That Hid Beside It
The study also found a different impurity whose mass was closer to +57 Da. This one arose when an extra glycine building block was inserted during chain assembly.1
A one-dalton difference sounds obvious when the values are written on a page: 56 is not 57. But an instrument does not report chemistry in neat whole numbers. Signals have shapes, molecules form different charged versions, and measurements have finite resolving power.
Think about two suitcases on a scale that rounds to the nearest pound. One may weigh 49.6 pounds and the other 50.4 pounds, yet the display could make them look the same. Add crowding, noise, and overlapping bags on the belt, and the distinction becomes harder.
In the peptide study, the +57 Da glycine-insertion impurity substantially overlapped with the +56 Da tert-butylation region under low-resolution mass spectrometry.1 The molecules were not the same. The initial view simply lacked enough detail to separate the explanations confidently.
High-resolution mass spectrometry changed that view. It measures mass precisely enough to distinguish near-neighbors that lower-resolution measurement may combine. The difference is not that one instrument sees molecules and the other does not. The difference is how finely the instrument can separate close possibilities.
This is a central lesson for anyone reading peptide test results: a mass that looks right after rounding may still fit more than one chemical explanation.
When the “Impurity” Is a Temporary Hitchhiker
The most counterintuitive finding came from signals that did not necessarily represent a permanent change to the peptide at all.
Before a mass spectrometer can measure a peptide, it must convert molecules in solution into charged particles in the gas phase. A common technique called electrospray ionization performs this transition by producing tiny charged droplets. As solvent evaporates, charged molecules enter the instrument.
During that process, a peptide may travel with a loosely associated solvent molecule, metal ion, or cluster. Analysts call this temporary companion an adduct.
Picture a person entering an airport scanner with a receipt stuck to a jacket. The scanner records the person plus the paper. That does not mean the receipt has become part of the fabric.
Liu and colleagues found that some residual +56-like signals came from noncovalent adducts and solvent-cluster species formed during electrospray ionization.1 Those signals were real measurements, but the easiest interpretation could have been wrong. They did not necessarily mean that a +56 Da group had been permanently attached during peptide synthesis.
This is where analytical experience matters. The question is no longer simply, “Is there an extra signal?” The better questions are:
| Question | What it helps reveal |
|---|---|
| Does the component separate as its own chromatographic peak? | Whether it behaves like a distinct component in the mixture |
| What is the accurate mass? | Which molecular formulas remain plausible |
| How does the signal behave under different measurement conditions? | Whether it may be a temporary adduct or cluster |
| What fragments appear when the molecule is broken into pieces? | Where a structural change may be located |
| Does the proposed explanation fit the synthesis process? | Whether the interpretation is chemically credible |
The instrument detects the signal. The method and the analyst determine what the signal can responsibly support.
Chromatography: Separating the Crowd
If mass spectrometry is a highly precise scale, chromatography is the line that lets one traveler step onto the scale at a time.
A peptide sample can contain the intended molecule, truncated chains, extended chains, deletion or insertion sequences, modified forms, residual reagents, and degradation products. Some of these components are chemically similar enough that complete separation is difficult. The EMA’s current synthetic-peptide guideline explicitly notes that the desired peptide and structurally related pre- and post-eluting impurities are not always completely separated during purification.2
Liquid chromatography sends the sample through a column. Different components interact with the column and solvent differently, so they emerge at different times. The resulting chromatogram shows peaks rather than molecular identities. A peak indicates that something reached the detector during a particular window.
That is already valuable. It can reveal that the sample contains more than one component and estimate how much detector response belongs to each peak. But retention time alone is not a molecular name.
Coupling chromatography to high-resolution mass spectrometry provides two complementary views: when a component arrives and what accurate mass evidence it carries. In a 2018 study of synthetic human C-peptide, researchers used LC-HRMS to identify, confirm, and quantify more than 65 structurally related impurities.3 That example shows how much chemical complexity can sit behind a sample that might otherwise be summarized by one purity percentage.
Why “Orthogonal” Testing Matters
Laboratories often use the word orthogonal. It sounds mathematical, but the idea is simple: use independent methods that look at the sample in different ways.
A security team would not identify a person from height alone. It might combine a photograph, an identification document, a fingerprint, and contextual information. Each clue has limitations. Agreement among independent clues creates confidence.
Peptide analysis follows the same logic.
| Method or evidence | Plain-English role | Limitation when used alone |
|---|---|---|
| Chromatography | Separates a mixture into different arrivals | A peak is not a complete identity |
| Accurate-mass MS | Measures molecular mass in fine detail | Different structures can still share or nearly share a mass |
| MS/MS fragmentation | Breaks a molecule into informative pieces | Coverage and interpretation depend on the molecule and method |
| Amino acid analysis | Measures the overall building-block composition | It may not fully establish order or modification location |
| NMR or other structural tools | Examines structural features in another way | Suitability depends on peptide size, concentration, and question |
| Manufacturing context | Tests whether an explanation fits the process | Context cannot replace direct analytical evidence |
A 2026 regulatory review describes this need directly: peptide complexity calls for comprehensive, orthogonal analytical approaches, with mass spectrometry and nuclear magnetic resonance providing complementary information.4 Current regulatory guidance likewise expects characterization, impurity control, and validated analytical procedures suited to the peptide and the question being asked.2
Orthogonal does not mean “run every instrument.” It means choose methods whose strengths compensate for one another’s blind spots.
Why This Matters Beyond One Academic Paper
The September study focused on a particular 36-residue model peptide, not every peptide in commerce. It would be inaccurate to claim that every +56 Da signal always has exactly four causes.
Its broader lesson is stronger precisely because it is modest: similar analytical appearances can conceal different chemical realities.
That lesson applies whenever a result is compressed into a simple label:
“Purity: 99%.”
“Mass confirmed.”
“Pass.”
Each statement may be useful. None explains the entire evidence chain. A high purity percentage does not identify every minor peak. A matching nominal mass does not prove sequence or locate a modification. A passing result is only meaningful when the method, specification, and sample context are clear.
Synthetic peptides are especially demanding because many impurities closely resemble the intended product. They may differ by one missing building block, one extra building block, a swapped stereochemical form, oxidation, deamidation, an incomplete protective-group removal, or another small structural change. Modern guidance recognizes peptides as a class requiring specific manufacturing and analytical controls rather than a one-size-fits-all test.2
For clinics, compounding pharmacies, developers, and informed consumers, the practical takeaway is not to memorize tert-butyl chemistry. It is to ask better questions about the evidence:
Was the sample separated? Was identity supported by accurate mass or sequence information? Were unexpected peaks investigated? Were the methods appropriate for this peptide and matrix? Can the laboratory explain what the result does and does not establish?
Those questions move the conversation from paperwork to measurement.
What a Defensible Answer Looks Like
A defensible analytical conclusion does not pretend uncertainty has disappeared. It makes uncertainty visible and then reduces it with evidence.
The process begins with a clear question. Are we checking whether the expected peptide is present? Measuring chromatographic purity? Quantifying content? Investigating an unknown peak? Looking for a specific degradation pathway? These are related questions, but they are not interchangeable.
Next comes separation. If multiple components are present, chromatography helps keep their signals from being interpreted as one blended answer.
Then comes structural evidence. Accurate mass narrows the possibilities. Fragmentation can show which part of a chain carries a difference. Other techniques can provide independent confirmation when the risk or ambiguity warrants it.
Finally, the interpretation must fit the chemistry. An impurity assignment is stronger when it matches a plausible manufacturing or degradation pathway and, ideally, when a process change alters that impurity in the predicted direction. The new +56 Da study did exactly that: the researchers paired analytical assignments with targeted synthesis changes that reduced the relevant byproducts.1
That is what turns a peak into an explanation.
The Bottom Line
A laboratory signal can be precise and still be misunderstood.
In one newly published peptide study, signals near +56 Da came from several sources: genuine chemical modifications, an extra glycine building block that sat close in mass, and temporary adducts formed during measurement.1 Lower-resolution measurement blurred some of those differences. Chromatographic behavior, high-resolution mass data, and chemical investigation helped separate them.
The result is a useful reminder for the entire peptide field:
A signal is a clue. A defensible conclusion comes from independent clues that agree.
At Vanguard Laboratory, that is the standard behind meaningful peptide analysis. The goal is not merely to produce a number. It is to understand what the number can support, what it cannot, and which additional evidence is needed to close the gap.
References
- Liu W, Zhu H, Wang Y, et al. “Possible Origin and Suppression of Apparent +56 Da Impurities during Peptide Synthesis.” Journal of Pharmaceutical and Biomedical Analysis. 2026.
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides. Adopted December 4, 2025; effective June 1, 2026.
- Li M, Josephs RD, Daireaux A, et al. “Identification and accurate quantification of structurally related peptide impurities in synthetic human C-peptide by liquid chromatography-high resolution mass spectrometry.” Analytical and Bioanalytical Chemistry. 2018;410:5059–5070.
- Yang E-J, Kim SH, Kim A, et al. “Regulatory and analytical considerations for the quality assessment of peptide drugs.” Journal of Pharmaceutical Investigation. 2026.